🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

RecruitingPhase 3Ages 19 Years - anyAllHuons Co., Ltd.
NCT07335211 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults aged 19 years and older * Participants diagnosed with POAG or OH * Have fully explained and understood the study and have voluntarily given written informed consent. Exclusion Criteria: * Acute or chronic angle-closure glaucoma * Congenital glaucoma, secondary glaucoma (open-angle glaucoma)
💊

What it tests

  • HUC3-637
  • HUC3-637-R
📍

Where

1 site
Kangbuk Samsung Hospital
Seoul, South Korea
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy